Deanna M Barch1. 1. Department of Psychology, Washington University, One Brookings Drive, Box 1125, St Louis, MO 63130, USA.
Abstract
RATIONALE: The goal of this paper is to briefly overview human studies that have examined pharmacological agents designed to enhance working memory function, with the idea of providing clues as to promising avenues to follow for the development of drugs likely to enhance working memory and other cognitive processes in individuals with schizophrenia. OBJECTIVES: We reviewed the studies that have used pharmacological agents designed to target the dopamine system, the noradrenergic system, the acetycholine system, the serotonin system, and the glycine site on NMDA receptors. RESULTS: There are a large number of studies suggesting that dopamine agents can enhance working memory, though there remain conflicting issues regarding the role that baseline performance plays in modulating the influence of drug and the importance of different dopamine receptors. There is also consistent evidence that cholinesterase inhibitors can enhance working memory function, potentially through improved encoding of the information. There is less consistent evidence that noradrenergic alpha-2 agonists consistently improve working memory in humans, despite the large animal literature suggesting that these agents should have a beneficial effect on memory. As of yet, there is little evidence that agents targeting the glycine site of the NMDA receptor improve working memory, and data to suggest that enhancement of the serotonin system impairs working memory. CONCLUSIONS: Compounds geared towards enhancing the dopamine system and the acetycholine system remain promising avenues for the development of pro-cognitive drugs, though further work is clearly needed on developing agents that may more selectively target specific receptors.
RATIONALE: The goal of this paper is to briefly overview human studies that have examined pharmacological agents designed to enhance working memory function, with the idea of providing clues as to promising avenues to follow for the development of drugs likely to enhance working memory and other cognitive processes in individuals with schizophrenia. OBJECTIVES: We reviewed the studies that have used pharmacological agents designed to target the dopamine system, the noradrenergic system, the acetycholine system, the serotonin system, and the glycine site on NMDA receptors. RESULTS: There are a large number of studies suggesting that dopamine agents can enhance working memory, though there remain conflicting issues regarding the role that baseline performance plays in modulating the influence of drug and the importance of different dopamine receptors. There is also consistent evidence that cholinesterase inhibitors can enhance working memory function, potentially through improved encoding of the information. There is less consistent evidence that noradrenergic alpha-2 agonists consistently improve working memory in humans, despite the large animal literature suggesting that these agents should have a beneficial effect on memory. As of yet, there is little evidence that agents targeting the glycine site of the NMDA receptor improve working memory, and data to suggest that enhancement of the serotonin system impairs working memory. CONCLUSIONS: Compounds geared towards enhancing the dopamine system and the acetycholine system remain promising avenues for the development of pro-cognitive drugs, though further work is clearly needed on developing agents that may more selectively target specific receptors.
Authors: S E Roitman; V Mitropoulou; R S Keefe; J M Silverman; M Serby; P D Harvey; D A Reynolds; R C Mohs; L J Siever Journal: Schizophr Res Date: 2000-02-14 Impact factor: 4.939
Authors: Venkata S Mattay; Terry E Goldberg; Francesco Fera; Ahmad R Hariri; Alessandro Tessitore; Michael F Egan; Bhaskar Kolachana; Joseph H Callicott; Daniel R Weinberger Journal: Proc Natl Acad Sci U S A Date: 2003-04-25 Impact factor: 11.205
Authors: D L Levy; M Smith; D Robinson; D Jody; G Lerner; J Alvir; S H Geisler; S R Szymanski; A Gonzalez; D I Mayerhoff Journal: Biol Psychiatry Date: 1993-10-15 Impact factor: 13.382
Authors: P Jäkälä; J Sirviö; M Riekkinen; E Koivisto; K Kejonen; M Vanhanen; P Riekkinen Journal: Neuropsychopharmacology Date: 1999-02 Impact factor: 7.853
Authors: Michael J Coleman; Olga Krastoshevsky; Xiawei Tu; Nancy R Mendell; Deborah L Levy Journal: Schizophr Res Date: 2012-05-27 Impact factor: 4.939
Authors: Alexandre Schaefer; Todd S Braver; Jeremy R Reynolds; Gregory C Burgess; Tal Yarkoni; Jeremy R Gray Journal: J Neurosci Date: 2006-10-04 Impact factor: 6.167
Authors: Kathrin Finke; Chris M Dodds; Peter Bublak; Ralf Regenthal; Frank Baumann; Tom Manly; Ulrich Müller Journal: Psychopharmacology (Berl) Date: 2010-03-30 Impact factor: 4.530
Authors: Ulrich Müller; Luke Clark; Minh L Lam; Rebecca M Moore; C Louise Murphy; Nicola K Richmond; Ranbir S Sandhu; Ingrid A Wilkins; David K Menon; Barbara J Sahakian; Trevor W Robbins Journal: Psychopharmacology (Berl) Date: 2005-10-19 Impact factor: 4.530